The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload

Experimental Physiology

Volumn 98, Issue 8, 2013, Pages 1274-1278

  Janssen, Wiebke ^a   Schermuly, Ralph Theo ^a   Kojonazarov, Baktybek ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR;

ARTICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OVERLOAD; HEART RIGHT VENTRICLE PRESSURE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE;

EID: 84880678637     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.069138     Document Type: Article

References (30)

1. Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E & Nielsen-Kudsk JE (2008). Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 10, 1158-1165.
2. Arnold WP, Mittal CK, Katsuki S & Murad F (1977). Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A 74, 3203-3207.
3. Bogaard H, Natarajan R, Henderson S, Long C, Kraskauskas D, Smithson L, Ockaili R, McCord JM & Voelkel NF (2009). Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120, 1951-1969.
4. Borgdorff MA, Bartelds B, Dickinson MG, Boersma B, Weij M, Zandvoort A, Sillje HH, Steendijk P, de Vroomen M & Berger RM (2012). Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail 14, 1067-1074.
5. Chin KM, Kim NH & Rubin LJ (2005). The right ventricle in pulmonary hypertension. Coron Artery Dis 16, 13-8.
6. Dell'Italia LJ (2012). Anatomy and physiology of the right ventricle. Cardiol Clin 30, 167-187.
7. Eddahibi S, Raffestin B, Le Monnier de Gouville AC & Adnot S (1998). Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br J Pharmacol 125, 681-688.
8. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M & Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353, 2148-2157.
9. Kang KK, Ahn GJ, Sohn YS, Ahn BO & Kim WB (2003). DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. J Int Med Res 31, 517-528.
10. Kojonazarov B, Sydykov A, Pullamsetti SS, Luitel H, Dahal BK, Kosanovic D, Tian X, Majewski M, Baumann C, Evans S, Phillips P, Fairman D, Davie N, Wayman C, Kilty I, Weissmann N, Grimminger F, Seeger W, Ghofrani HA & Schermuly RT (2012). Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. Int J Cardiol ; DOI: 10.1016/.921.60.2102.dracji.j
11. Kuhn M (2009). Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent Cardiovasc Res 82, 4-6.
12. Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, Kretschmer A, Stasch JP, Seeger W, Ghofrani HA & Schermuly RT (2012). The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 7, e43433.
13. Marsboom G & Janssens S (2004). Models for pulmonary hypertension. Drug Discover Today: Disease Models 1, 289-296.
14. Miller CL & Yan C (2010). Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J Cardiovasc Transl Res 3, 507-515.
15. Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP, Vonk Noordegraaf A & van der Laarse WJ (2010). Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 36, 800-807.
16. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E & Kass DA (2009). Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53, 207-215.
17. Nagendran J, Archer S, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka I, Ross D, Light P, Dyck J & Michelakis E (2007). Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116, 238-248.
18. Pak O, Janssen W, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT & Weissmann N (2010). Animal models of pulmonary hypertension: role in translational research. Drug Discover Today: Disease Models 7, 89-97.
19. Pokreisz P, Marsboom G & Janssens S (2007). Pressure overload-induced right ventricular dysfunction and remodelling in experimental pulmonary hypertension: the right heart revisited. Eur Heart J Suppl 9, H75-H84.
20. Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD & Kemp-Harper BK (2009). Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther 124, 279-300.
21. Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R & Klein M (2009). Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 82, 30-39.
22. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W & Grimminger F (2004). Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169, 39-45.
23. Schermuly RT, Ghofrani HA, Wilkins MR & Grimminger F (2011). Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 8, 443-455.
24. Takimoto E, Champion H, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y & Kass DA (2005). Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11, 214-222.
25. Thorsen LB, Eskildsen-Helmond Y, Zibrandtsen H, Stasch JP, Simonsen U & Laursen BE (2010). BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats. Eur J Pharmacol 647, 147-154.
26. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, Postmus PE & Vonk-Noordegraaf A (2007). Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28, 1250-1257.
27. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P & Gibbs JS (2005). Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171, 1292-1297.
28. 2+ handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. Hypertension 59, 355-362.
29. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, Koenke T, O'Rourke B, Champion HC, Crow MT & Kass DA (2008). Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal 20, 2231-2236.
30. Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang C, Wharton J & Wilkins MR (2009). Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 34, 948-957.